Matthew H. Taylor

Providence Portland Medical Center — United States

Medicine · Health Sciences

47h-index19.8kcitations284works10.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(77), Melanoma and MAPK Pathways(49), CAR-T cell therapy research(37), Thyroid Cancer Diagnosis and Treatment(35), Lung Cancer Treatments and Mutations(35)

Publications281 total

Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma
JCO oncology advances.·2026Open Access
Understanding the kidney replacement therapy decision-making process
BMC Nephrology·2025Open Access
636 Addition of GITR agonist to a dark matter cancer vaccine and anti-PD-1 increases regulatory T cell numbers without appearing to impact therapeutic efficacy
Regular and Young Investigator Award Abstracts·2025Open Access
Endothelial cells as targets of immune checkpoint blockade
Journal for ImmunoTherapy of Cancer·2025Open Access
Model Organisms for Emergent Misalignment
arXiv (Cornell University)·2025Open Access
Table 3 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Data from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Table 4 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
2025Open Access
Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.
Journal of Clinical Oncology·2025· 1 cited
Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.
Journal of Clinical Oncology·2025· 2 cited
Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions
Journal of Clinical Oncology·2025· 1 cited
Abstract 855: Dynamics of T cell and T cell receptor following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
Cancer Research·2025· 2 cited
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i> V600-Mutant Metastatic Melanoma
Clinical Cancer Research·2025· 2 citedOpen Access
Abstract A107: Updated results from a study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, in melanoma
Cancer Immunology Research·2025
Electrostatic Particle Ionization for Reduction in Livestock and Potash Dust
Atmosphere·2025· 1 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Marcia S. Brose(10), Lori J. Wirth(8), Corina E. Dutcus(8), Manish R. Patel(8), James L. Gulley(8), Patrick A. Ott(7), Vivek Subbiah(7), Justin F. Gainor(7), Paolo A. Ascierto(6), Viola W. Zhu(6), Anja von Heydebreck(6), Kenneth F. Grossmann(5), Sanjiv S. Agarwala(5), Robert C. Doebele(5), Giuseppe Curigliano(5), Aaron S. Mansfield(5), John Nemunaitis(5), Montaser Shaheen(4), Anna F. Farago(4), Afshin Dowlati(4)